SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2025-05-21 09:54Core Viewpoint - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., is experiencing a decline in stock price and profitability, with a high PE ratio compared to industry averages, indicating potential overvaluation in the context of its recent financial performance [1][2]. Company Overview - The company specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, including ultrasound diagnostic devices, endoscopes, minimally invasive surgical products, and cardiovascular intervention products [1]. - With over 20 years of experience in the ultrasound industry, the company is recognized as a high-tech enterprise and has developed core technologies for color Doppler ultrasound machines and probes, leading the domestic market [1]. Financial Performance - For Q1 2025, the company reported a revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.07 million yuan, down 91.94% year-on-year, with a gross margin of 63.19% [1]. Market Position - The company ranks second among domestic manufacturers in market share for ultrasound products and tenth globally, reflecting its strong brand influence and competitive edge in the industry [1]. - As of May 21, the company's stock closed at 31.9 yuan, with a rolling PE ratio of 274.53, significantly higher than the industry average of 49.38 and the median of 35.87, placing it at the 119th position in the industry [2]. Capital Flow - On May 21, the company saw a net inflow of 16.28 million yuan in main funds, with a total inflow of 17.06 million yuan over the past five days, indicating a generally positive capital flow trend [1].